Dashboard
Manage Tickers

SRPT Sarepta Therapeutics, Inc.

Nasdaq sarepta.com


$ 21.46 $ -0.53 (-2.41 %)    

Tuesday, 14-Oct-2025 19:36:29 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 21.43
$ 21.58
$ 21.31 x 2
$ 22.30 x 20
$ 20.92 - $ 21.82
$ 10.42 - $ 138.81
3,747,051
na
2.09B
$ 0.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-02-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-02-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-26-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 10-31-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 02-28-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 02-25-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

whats-going-on-sarepta-stock-on-wednesday
What's Going On Sarepta Stock On Wednesday?
10/08/2025 15:19:16

Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.

sarepta-therapeutics-to-present-results-from-emergene-phase-3-study-on-expression-of-sgcb-and-safety-following-bidridistrogene-xeboparvovec-treatment-in-patients-with-lgmd2er4-at-wms-2025-congress
Sarepta Therapeutics To Present Results Fr...
10/03/2025 12:36:01

taysha-gene-therapies-canaan-ondas-holdings-and-other-big-stocks-moving-higher-on-thursday
Taysha Gene Therapies, Canaan, Ondas Holdi...
10/02/2025 16:29:57

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

watching-sarepta-therapeutics-shares-are-moving-higher-traders-circulate-linkedin-post-from-us-fda-drug-regulator-george-tidmarsh
Watching Sarepta Therapeutics; Shares Are ...
09/29/2025 17:09:31

https://www.linkedin.com/posts/george-f-tidmarsh-972061b_cder-will-be-evaluating-surrogate-endpoints-activity-73783970832230563...

this-sarepta-therapeutics-analyst-turns-bullish-here-are-top-5-upgrades-for-monday
This Sarepta Therapeutics Analyst Turns Bu...
09/22/2025 12:43:32

bmo-capital-upgrades-sarepta-therapeutics-to-outperform-maintains-price-target-to-50
BMO Capital Upgrades Sarepta Therapeutics ...
09/22/2025 11:21:53

BMO Capital analyst Kostas Biliouris upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Market Perform to Outperform and maint...

expert-outlook-sarepta-therapeutics-through-the-eyes-of-43-analysts
Expert Outlook: Sarepta Therapeutics Throu...
09/15/2025 14:02:08

guggenheim-reiterates-buy-on-sarepta-therapeutics-maintains-22-price-target
Guggenheim Reiterates Buy on Sarepta Thera...
09/15/2025 12:42:32

Guggenheim analyst Debjit Chattopadhyay reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $22 price tar...

leerink-partners-maintains-market-perform-on-sarepta-therapeutics-raises-price-target-to-15
Leerink Partners Maintains Market Perform ...
09/09/2025 14:08:01

Leerink Partners analyst Joseph Schwartz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Market Perform and raises the p...

Core News & Articles
Elanco Animal Health Will Replace Sarepta ...
08/26/2025 21:20:48

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250826-1479707/1479707_brkl6.pdf

forecasting-the-future-44-analyst-projections-for-sarepta-therapeutics
Forecasting The Future: 44 Analyst Project...
08/25/2025 12:00:45

hc-wainwright--co-reiterates-sell-on-sarepta-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Sell on Sar...
08/25/2025 11:38:23

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $...

b-of-a-securities-maintains-underperform-on-sarepta-therapeutics-lowers-price-target-to-16
B of A Securities Maintains Underperform o...
08/21/2025 17:45:56

B of A Securities analyst Tazeen Ahmad maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Underperform and lowers the price...

whats-going-on-with-sarepta-shares-thursday
What's Going On With Sarepta Shares Thursday?
08/21/2025 14:26:29

sarepta-therapeutics-to-refinance-700m-convertible-notes-extends-maturity-to-2030
Sarepta Therapeutics To Refinance $700M Co...
08/21/2025 11:09:36

b-of-a-securities-maintains-underperform-on-sarepta-therapeutics-raises-price-target-to-17
B of A Securities Maintains Underperform o...
08/20/2025 12:49:16

B of A Securities analyst Tazeen Ahmad maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Underperform and raises the price...

deutsche-bank-maintains-sell-on-sarepta-therapeutics-raises-price-target-to-12
Deutsche Bank Maintains Sell on Sarepta Th...
08/15/2025 17:42:32

Deutsche Bank analyst David Hoang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from ...

Core News & Articles
Arrowhead Receives $100M Milestone From Sa...
08/13/2025 20:30:04

- Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed...

how-do-investors-really-feel-about-sarepta-therapeutics
How Do Investors Really Feel About Sarepta...
08/13/2025 13:00:38

vinay-prasads-comeback-to-fda-sparks-debate-over-regulatory-direction
Vinay Prasad's Comeback To FDA Sparks Deba...
08/11/2025 12:45:28

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vac...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION